Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.

Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY.

PLoS One. 2011;6(8):e23790. doi: 10.1371/journal.pone.0023790. Epub 2011 Aug 17.

2.

Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.

Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, Mak CS, Leung TH, Chan KK, Ngan HY.

PLoS One. 2012;7(12):e52578. doi: 10.1371/journal.pone.0052578. Epub 2012 Dec 20. Erratum in: PLoS One. 2014;9(10):e110304.

3.
4.

Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.

Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW.

Mol Cancer Ther. 2008 Jul;7(7):2022-32. doi: 10.1158/1535-7163.MCT-08-0188.

5.

Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis.

Wang Y, Chan DW, Liu VW, Chiu P, Ngan HY.

Clin Cancer Res. 2010 May 1;16(9):2529-39. doi: 10.1158/1078-0432.CCR-10-0018. Epub 2010 Apr 13. Erratum in: Clin Cancer Res. 2016 Mar 1;22(5):1296.

6.

Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.

Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS.

Am J Pathol. 2011 Feb;178(2):537-47. doi: 10.1016/j.ajpath.2010.10.020.

7.

FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K.

Clin Cancer Res. 2014 Mar 15;20(6):1477-88. doi: 10.1158/1078-0432.CCR-13-2311. Epub 2014 Jan 22.

8.

FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.

Fan Q, Cai Q, Xu Y.

Oncotarget. 2015 Sep 29;6(29):27688-99. doi: 10.18632/oncotarget.4280.

9.

Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma.

Jiang L, Wang P, Chen H.

Ups J Med Sci. 2014 Nov;119(4):324-32. doi: 10.3109/03009734.2014.960053. Epub 2014 Sep 18.

10.

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.

Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY.

Oncotarget. 2015 Feb 10;6(4):2349-65.

11.

Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.

Jiang L, Wu X, Wang P, Wen T, Yu C, Wei L, Chen H.

J Cancer Res Clin Oncol. 2015 Jun;141(6):971-81. doi: 10.1007/s00432-014-1872-3. Epub 2014 Nov 13.

PMID:
25391371
12.

DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.

Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y, Liang RR, Leung TH, Xu D, Chan KK, Yao KM, Tsang BK, Ngan HY.

Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.

13.

Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.

Zhang X, Cheng L, Minn K, Madan R, Godwin AK, Shridhar V, Chien J.

Oncotarget. 2014 Nov 30;5(22):11365-80.

14.

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.

Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.

Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.

15.

Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K.

Cancer Res. 2013 Jul 1;73(13):3987-96. doi: 10.1158/0008-5472.CAN-12-3859. Epub 2013 Apr 18.

16.

The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.

Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, Cui J, Le X, Huang S, Xie K.

Clin Cancer Res. 2013 Jan 1;19(1):62-72. doi: 10.1158/1078-0432.CCR-12-1588. Epub 2012 Nov 7.

17.

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, Khongkow P, Lam EW, Cheung AN.

PLoS One. 2014 Nov 20;9(11):e113478. doi: 10.1371/journal.pone.0113478. eCollection 2014.

19.

Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.

Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P, Al-Kuraya KS.

Haematologica. 2012 Jul;97(7):1092-100. doi: 10.3324/haematol.2011.053421. Epub 2012 Jan 22.

20.

FOXM1 regulated by ERK pathway mediates TGF-β1-induced EMT in NSCLC.

Kong FF, Zhu YL, Yuan HH, Wang JY, Zhao M, Gong XD, Liu F, Zhang WY, Wang CR, Jiang B.

Oncol Res. 2014;22(1):29-37. doi: 10.3727/096504014X14078436004987.

PMID:
25700356

Supplemental Content

Support Center